Global Rare Disease Drug Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
Table of Contents1 Report Overview
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Rare Disease Drug Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 Above 1
1.2.3 0.65?1
1.2.4 Below 0.1
1.3 Market Segment by Application
1.3.1 Global Rare Disease Drug Market Share by Application (2017 VS 2021 VS 2028)
1.3.2 Hospital Pharmacies
1.3.3 Speciality Pharmacies
1.3.4 Retail pharmacies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Rare Disease Drug Market Size (2017-2028)
2.1.1 Global Rare Disease Drug Revenue (2017-2028)
2.1.2 Global Rare Disease Drug Sales (2017-2028)
2.2 Global Rare Disease Drug Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.2.1 Global Rare Disease Drug Sales by Regions (2017-2022)
2.2.2 Global Rare Disease Drug Revenue by Regions (2017-2022)
2.3 Global Rare Disease Drug Market Size Forecast by Region
2.3.1 Global Rare Disease Drug Sales Forecast by Region (2023-2028)
2.3.2 Global Rare Disease Drug Revenue Forecast by Region (2023-2028)
2.4 Global Top Rare Disease Drug Regions (Countries) Ranking by Market Size
2.5 Rare Disease Drug Market Dynamics
2.5.1 Rare Disease Drug Market Trends
2.5.2 Rare Disease Drug Market Drivers
2.5.3 Rare Disease Drug Market Challenges
2.5.4 Rare Disease Drug Market Restraints
3 Competitive Landscape by Manufacturers
3.1 Global Top Rare Disease Drug Manufacturers by Sales (2017-2022)
3.1.1 Global Rare Disease Drug Sales by Manufacturers (2017-2022)
3.1.2 Global Rare Disease Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global 5 and 10 Largest Manufacturers by Rare Disease Drug Sales in 2021
3.2 Global Top Manufacturers Rare Disease Drug by Revenue
3.2.1 Global Rare Disease Drug Revenue by Manufacturers (2017-2022)
3.2.2 Top Rare Disease Drug Manufacturers Covered: Ranking by Revenue
3.2.3 Global Rare Disease Drug Revenue Share by Manufacturers (2017-2022)
3.2.4 Global Rare Disease Drug Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Rare Disease Drug as of 2021)
3.4 Global Rare Disease Drug Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Rare Disease Drug Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Rare Disease Drug Market
3.7 Key Manufacturers Rare Disease Drug Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Rare Disease Drug Market Size by Type
4.1 Global Rare Disease Drug Historic Market Review by Type (2017-2022)
4.1.1 Global Rare Disease Drug Sales Market Share by Type (2017-2022)
4.1.2 Global Rare Disease Drug Revenue Market Share by Type (2017-2022)
4.1.3 Rare Disease Drug Price by Type (2017-2022)
4.2 Global Rare Disease Drug Market Estimates and Forecasts by Type (2023-2028)
4.2.1 Global Rare Disease Drug Sales Forecast by Type (2023-2028)
4.2.2 Global Rare Disease Drug Revenue Forecast by Type (2023-2028)
4.2.3 Rare Disease Drug Price Forecast by Type (2023-2028)
5 Global Rare Disease Drug Market Size by Application
5.1 Global Rare Disease Drug Historic Market Review by Application (2017-2022)
5.1.1 Global Rare Disease Drug Sales Market Share by Application (2017-2022)
5.1.2 Global Rare Disease Drug Revenue Market Share by Application (2017-2022)
5.1.3 Rare Disease Drug Price by Application (2017-2022)
5.2 Global Rare Disease Drug Market Estimates and Forecasts by Application (2023-2028)
5.2.1 Global Rare Disease Drug Sales Forecast by Application (2023-2028)
5.2.2 Global Rare Disease Drug Revenue Forecast by Application (2023-2028)
5.2.3 Rare Disease Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Rare Disease Drug Sales Breakdown by Company
6.1.1 North America Rare Disease Drug Sales by Company (2017-2022)
6.1.2 North America Rare Disease Drug Revenue by Company (2017-2022)
6.2 North America Rare Disease Drug Market Size by Type
6.2.1 North America Rare Disease Drug Sales by Type (2017-2028)
6.2.2 North America Rare Disease Drug Revenue by Type (2017-2028)
6.3 North America Rare Disease Drug Market Size by Application
6.3.1 North America Rare Disease Drug Sales by Application (2017-2028)
6.3.2 North America Rare Disease Drug Revenue by Application (2017-2028)
6.4 North America Rare Disease Drug Market Size by Country
6.4.1 North America Rare Disease Drug Sales by Country (2017-2028)
6.4.2 North America Rare Disease Drug Revenue by Country (2017-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Rare Disease Drug Sales Breakdown by Company
7.1.1 Europe Rare Disease Drug Sales by Company (2017-2022)
7.1.2 Europe Rare Disease Drug Revenue by Company (2017-2022)
7.2 Europe Rare Disease Drug Market Size by Type
7.2.1 Europe Rare Disease Drug Sales by Type (2017-2028)
7.2.2 Europe Rare Disease Drug Revenue by Type (2017-2028)
7.3 Europe Rare Disease Drug Market Size by Application
7.3.1 Europe Rare Disease Drug Sales by Application (2017-2028)
7.3.2 Europe Rare Disease Drug Revenue by Application (2017-2028)
7.4 Europe Rare Disease Drug Market Size by Country
7.4.1 Europe Rare Disease Drug Sales by Country (2017-2028)
7.4.2 Europe Rare Disease Drug Revenue by Country (2017-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Rare Disease Drug Sales Breakdown by Company
8.1.1 Asia Pacific Rare Disease Drug Sales by Company (2017-2022)
8.1.2 Asia Pacific Rare Disease Drug Revenue by Company (2017-2022)
8.2 Asia Pacific Rare Disease Drug Market Size by Type
8.2.1 Asia Pacific Rare Disease Drug Sales by Type (2017-2028)
8.2.2 Asia Pacific Rare Disease Drug Revenue by Type (2017-2028)
8.3 Asia Pacific Rare Disease Drug Market Size by Application
8.3.1 Asia Pacific Rare Disease Drug Sales by Application (2017-2028)
8.3.2 Asia Pacific Rare Disease Drug Revenue by Application (2017-2028)
8.4 Asia Pacific Rare Disease Drug Market Size by Region
8.4.1 Asia Pacific Rare Disease Drug Sales by Region
8.4.2 Asia Pacific Rare Disease Drug Revenue by Region
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Rare Disease Drug Sales Breakdown by Company
9.1.1 Latin America Rare Disease Drug Sales by Company (2017-2022)
9.1.2 Latin America Rare Disease Drug Revenue by Company (2017-2022)
9.2 Latin America Rare Disease Drug Market Size by Type
9.2.1 Latin America Rare Disease Drug Sales by Type (2017-2028)
9.2.2 Latin America Rare Disease Drug Revenue by Type (2017-2028)
9.3 Latin America Rare Disease Drug Market Size by Application
9.3.1 Latin America Rare Disease Drug Sales by Application (2017-2028)
9.3.2 Latin America Rare Disease Drug Revenue by Application (2017-2028)
9.4 Latin America Rare Disease Drug Market Size by Country
9.4.1 Latin America Rare Disease Drug Sales by Country (2017-2028)
9.4.2 Latin America Rare Disease Drug Revenue by Country (2017-2028)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Rare Disease Drug Sales Breakdown by Company
10.1.1 Middle East and Africa Rare Disease Drug Sales by Company (2017-2022)
10.1.2 Middle East and Africa Rare Disease Drug Revenue by Company (2017-2022)
10.2 Middle East and Africa Rare Disease Drug Market Size by Type
10.2.1 Middle East and Africa Rare Disease Drug Sales by Type (2017-2028)
10.2.2 Middle East and Africa Rare Disease Drug Revenue by Type (2017-2028)
10.3 Middle East and Africa Rare Disease Drug Market Size by Application
10.3.1 Middle East and Africa Rare Disease Drug Sales by Application (2017-2028)
10.3.2 Middle East and Africa Rare Disease Drug Revenue by Application (2017-2028)
10.4 Middle East and Africa Rare Disease Drug Market Size by Country
10.4.1 Middle East and Africa Rare Disease Drug Sales by Country (2017-2028)
10.4.2 Middle East and Africa Rare Disease Drug Revenue by Country (2017-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 U.A.E
11 Company Profiles
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Overview
11.1.3 Novartis AG Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.1.4 Novartis AG Rare Disease Drug Products and Services
11.1.5 Novartis AG Rare Disease Drug SWOT Analysis
11.1.6 Novartis AG Recent Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Corporation Information
11.2.2 Bristol-Myers Squibb Company Overview
11.2.3 Bristol-Myers Squibb Company Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.2.4 Bristol-Myers Squibb Company Rare Disease Drug Products and Services
11.2.5 Bristol-Myers Squibb Company Rare Disease Drug SWOT Analysis
11.2.6 Bristol-Myers Squibb Company Recent Developments
11.3 Celgene Corporation
11.3.1 Celgene Corporation Corporation Information
11.3.2 Celgene Corporation Overview
11.3.3 Celgene Corporation Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.3.4 Celgene Corporation Rare Disease Drug Products and Services
11.3.5 Celgene Corporation Rare Disease Drug SWOT Analysis
11.3.6 Celgene Corporation Recent Developments
11.4 F. Hoffmann-La Roche Ltd.
11.4.1 F. Hoffmann-La Roche Ltd. Corporation Information
11.4.2 F. Hoffmann-La Roche Ltd. Overview
11.4.3 F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.4.4 F. Hoffmann-La Roche Ltd. Rare Disease Drug Products and Services
11.4.5 F. Hoffmann-La Roche Ltd. Rare Disease Drug SWOT Analysis
11.4.6 F. Hoffmann-La Roche Ltd. Recent Developments
11.5 Pfizer, Inc.
11.5.1 Pfizer, Inc. Corporation Information
11.5.2 Pfizer, Inc. Overview
11.5.3 Pfizer, Inc. Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.5.4 Pfizer, Inc. Rare Disease Drug Products and Services
11.5.5 Pfizer, Inc. Rare Disease Drug SWOT Analysis
11.5.6 Pfizer, Inc. Recent Developments
11.6 Sanofi S.A.
11.6.1 Sanofi S.A. Corporation Information
11.6.2 Sanofi S.A. Overview
11.6.3 Sanofi S.A. Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.6.4 Sanofi S.A. Rare Disease Drug Products and Services
11.6.5 Sanofi S.A. Rare Disease Drug SWOT Analysis
11.6.6 Sanofi S.A. Recent Developments
11.7 Alexion Pharmaceuticals, Inc.
11.7.1 Alexion Pharmaceuticals, Inc. Corporation Information
11.7.2 Alexion Pharmaceuticals, Inc. Overview
11.7.3 Alexion Pharmaceuticals, Inc. Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.7.4 Alexion Pharmaceuticals, Inc. Rare Disease Drug Products and Services
11.7.5 Alexion Pharmaceuticals, Inc. Rare Disease Drug SWOT Analysis
11.7.6 Alexion Pharmaceuticals, Inc. Recent Developments
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Corporation Information
11.8.2 Eli Lilly and Company Overview
11.8.3 Eli Lilly and Company Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.8.4 Eli Lilly and Company Rare Disease Drug Products and Services
11.8.5 Eli Lilly and Company Rare Disease Drug SWOT Analysis
11.8.6 Eli Lilly and Company Recent Developments
11.9 Novo Nordisk A/S
11.9.1 Novo Nordisk A/S Corporation Information
11.9.2 Novo Nordisk A/S Overview
11.9.3 Novo Nordisk A/S Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.9.4 Novo Nordisk A/S Rare Disease Drug Products and Services
11.9.5 Novo Nordisk A/S Rare Disease Drug SWOT Analysis
11.9.6 Novo Nordisk A/S Recent Developments
11.10 AstraZeneca
11.10.1 AstraZeneca Corporation Information
11.10.2 AstraZeneca Overview
11.10.3 AstraZeneca Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.10.4 AstraZeneca Rare Disease Drug Products and Services
11.10.5 AstraZeneca Rare Disease Drug SWOT Analysis
11.10.6 AstraZeneca Recent Developments
11.11 Eisai Co., Ltd.
11.11.1 Eisai Co., Ltd. Corporation Information
11.11.2 Eisai Co., Ltd. Overview
11.11.3 Eisai Co., Ltd. Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.11.4 Eisai Co., Ltd. Rare Disease Drug Products and Services
11.11.5 Eisai Co., Ltd. Recent Developments
11.12 Daiichi Sankyo Company Limited
11.12.1 Daiichi Sankyo Company Limited Corporation Information
11.12.2 Daiichi Sankyo Company Limited Overview
11.12.3 Daiichi Sankyo Company Limited Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.12.4 Daiichi Sankyo Company Limited Rare Disease Drug Products and Services
11.12.5 Daiichi Sankyo Company Limited Recent Developments
11.13 Bayer AG
11.13.1 Bayer AG Corporation Information
11.13.2 Bayer AG Overview
11.13.3 Bayer AG Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.13.4 Bayer AG Rare Disease Drug Products and Services
11.13.5 Bayer AG Recent Developments
11.14 GlaxoSmithKline
11.14.1 GlaxoSmithKline Corporation Information
11.14.2 GlaxoSmithKline Overview
11.14.3 GlaxoSmithKline Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.14.4 GlaxoSmithKline Rare Disease Drug Products and Services
11.14.5 GlaxoSmithKline Recent Developments
11.15 Merck & Co., Inc.
11.15.1 Merck & Co., Inc. Corporation Information
11.15.2 Merck & Co., Inc. Overview
11.15.3 Merck & Co., Inc. Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.15.4 Merck & Co., Inc. Rare Disease Drug Products and Services
11.15.5 Merck & Co., Inc. Recent Developments
11.16 Johnson & Johnson
11.16.1 Johnson & Johnson Corporation Information
11.16.2 Johnson & Johnson Overview
11.16.3 Johnson & Johnson Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.16.4 Johnson & Johnson Rare Disease Drug Products and Services
11.16.5 Johnson & Johnson Recent Developments
11.17 Biogen, Inc.
11.17.1 Biogen, Inc. Corporation Information
11.17.2 Biogen, Inc. Overview
11.17.3 Biogen, Inc. Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.17.4 Biogen, Inc. Rare Disease Drug Products and Services
11.17.5 Biogen, Inc. Recent Developments
11.18 Takeda
11.18.1 Takeda Corporation Information
11.18.2 Takeda Overview
11.18.3 Takeda Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.18.4 Takeda Rare Disease Drug Products and Services
11.18.5 Takeda Recent Developments
11.19 Amgen, Inc.
11.19.1 Amgen, Inc. Corporation Information
11.19.2 Amgen, Inc. Overview
11.19.3 Amgen, Inc. Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.19.4 Amgen, Inc. Rare Disease Drug Products and Services
11.19.5 Amgen, Inc. Recent Developments
11.20 Deciphera
11.20.1 Deciphera Corporation Information
11.20.2 Deciphera Overview
11.20.3 Deciphera Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.20.4 Deciphera Rare Disease Drug Products and Services
11.20.5 Deciphera Recent Developments
11.21 Atara Biotherapeutics
11.21.1 Atara Biotherapeutics Corporation Information
11.21.2 Atara Biotherapeutics Overview
11.21.3 Atara Biotherapeutics Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.21.4 Atara Biotherapeutics Rare Disease Drug Products and Services
11.21.5 Atara Biotherapeutics Recent Developments
11.22 ProQR
11.22.1 ProQR Corporation Information
11.22.2 ProQR Overview
11.22.3 ProQR Rare Disease Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.22.4 ProQR Rare Disease Drug Products and Services
11.22.5 ProQR Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Rare Disease Drug Value Chain Analysis
12.2 Rare Disease Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Rare Disease Drug Production Mode & Process
12.4 Rare Disease Drug Sales and Marketing
12.4.1 Rare Disease Drug Sales Channels
12.4.2 Rare Disease Drug Distributors
12.5 Rare Disease Drug Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
List of TablesTable 1. Global Rare Disease Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Above 1
Table 3. Major Manufacturers of 0.65?1
Table 4. Major Manufacturers of Below 0.1
Table 5. Global Rare Disease Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Rare Disease Drug Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 7. Global Rare Disease Drug Sales by Region (2017-2022) & (K Doses)
Table 8. Global Rare Disease Drug Sales Market Share by Region (2017-2022)
Table 9. Global Rare Disease Drug Revenue by Region (2017-2022) & (US$ Million)
Table 10. Global Rare Disease Drug Revenue Market Share by Region (2017-2022)
Table 11. Global Rare Disease Drug Sales Forecast by Region (2023-2028) & (K Doses)
Table 12. Global Rare Disease Drug Sales Market Share Forecast by Region (2023-2028)
Table 13. Global Rare Disease Drug Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 14. Global Rare Disease Drug Revenue Market Share Forecast by Region (2023-2028)
Table 15. Top Rare Disease Drug Regions (Countries) Ranking by Market Size (US$ Million) in 2021
Table 16. Rare Disease Drug Market Trends
Table 17. Rare Disease Drug Market Drivers
Table 18. Rare Disease Drug Market Challenges
Table 19. Rare Disease Drug Market Restraints
Table 20. Global Rare Disease Drug Sales by Manufacturers (2017-2022) & (K Doses)
Table 21. Global Rare Disease Drug Sales Share by Manufacturers (2017-2022)
Table 22. Global Rare Disease Drug Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 23. Ranking of Global Top Rare Disease Drug Manufacturers by Revenue (US$ Million) in 2021
Table 24. Rare Disease Drug Revenue Share by Manufacturers (2017-2022)
Table 25. Global Rare Disease Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 26. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Rare Disease Drug as of 2021)
Table 27. Key Manufacturers Rare Disease Drug Average Selling Price (ASP) & (2017-2022) & (USD/Dose)
Table 28. Key Manufacturers Rare Disease Drug Plants/Factories Distribution
Table 29. Key Manufacturers Rare Disease Drug Area Served
Table 30. Date of Key Manufacturers Enter into Rare Disease Drug Market
Table 31. Key Manufacturers Rare Disease Drug Product Type
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Rare Disease Drug Sales (K Doses) by Type (2017-2022)
Table 34. Global Rare Disease Drug Sales Share by Type (2017-2022)
Table 35. Global Rare Disease Drug Revenue (US$ Million) Market Share by Type (2017-2022)
Table 36. Global Rare Disease Drug Price (K Doses) by Type (2017-2022)
Table 37. Global Rare Disease Drug Sales (K Doses) by Type (2023-2028)
Table 38. Global Rare Disease Drug Sales Share by Type (2023-2028)
Table 39. Global Rare Disease Drug Revenue (US$ Million) Market Share by Type (2023-2028)
Table 40. Global Rare Disease Drug Revenue Share by Type (2023-2028)
Table 41. Global Rare Disease Drug Price (K Doses) by Type (2023-2028)
Table 42. Global Rare Disease Drug Sales (K Doses) by Application (2017-2022)
Table 43. Global Rare Disease Drug Sales Share by Application (2017-2022)
Table 44. Global Rare Disease Drug Revenue (US$ Million) Market Share by Application (2017-2022)
Table 45. Global Rare Disease Drug Price (K Doses) by Application (2017-2022)
Table 46. Global Rare Disease Drug Sales (K Doses) by Application (2023-2028)
Table 47. Global Rare Disease Drug Sales Share by Application (2023-2028)
Table 48. Global Rare Disease Drug Revenue (US$ Million) Market Share by Application (2023-2028)
Table 49. Global Rare Disease Drug Revenue Share by Application (2023-2028)
Table 50. Global Rare Disease Drug Price (K Doses) by Application (2023-2028)
Table 51. North America Rare Disease Drug Sales by Company (2017-2022) & (K Doses)
Table 52. North America Rare Disease Drug Sales Market Share by Company (2017-2022)
Table 53. North America Rare Disease Drug Revenue by Company (2017-2022) & (US$ Million)
Table 54. North America Rare Disease Drug Revenue Market Share by Company (2017-2022)
Table 55. North America Rare Disease Drug Sales by Type (2017-2022) & (K Doses)
Table 56. North America Rare Disease Drug Sales by Type (2023-2028) & (K Doses)
Table 57. North America Rare Disease Drug Revenue by Type (2017-2022) & (US$ Million)
Table 58. North America Rare Disease Drug Revenue by Type (2023-2028) & (US$ Million)
Table 59. North America Rare Disease Drug Sales by Application (2017-2022) & (K Doses)
Table 60. North America Rare Disease Drug Sales by Application (2023-2028) & (K Doses)
Table 61. North America Rare Disease Drug Revenue by Application (2017-2022) & (US$ Million)
Table 62. North America Rare Disease Drug Revenue by Application (2023-2028) & (US$ Million)
Table 63. North America Rare Disease Drug Sales by Country (2017-2022) & (K Doses)
Table 64. North America Rare Disease Drug Sales by Country (2023-2028) & (K Doses)
Table 65. North America Rare Disease Drug Revenue by Country (2017-2022) & (US$ Million)
Table 66. North America Rare Disease Drug Revenue by Country (2023-2028) & (US$ Million)
Table 67. Europe Rare Disease Drug Sales by Company (2017-2022) & (K Doses)
Table 68. Europe Rare Disease Drug Sales Market Share by Company (2017-2022)
Table 69. Europe Rare Disease Drug Revenue by Company (2017-2022) & (US$ Million)
Table 70. Europe Rare Disease Drug Revenue Market Share by Company (2017-2022)
Table 71. Europe Rare Disease Drug Sales by Type (2017-2022) & (K Doses)
Table 72. Europe Rare Disease Drug Sales by Type (2023-2028) & (K Doses)
Table 73. Europe Rare Disease Drug Revenue by Type (2017-2022) & (US$ Million)
Table 74. Europe Rare Disease Drug Revenue by Type (2023-2028) & (US$ Million)
Table 75. Europe Rare Disease Drug Sales by Application (2017-2022) & (K Doses)
Table 76. Europe Rare Disease Drug Sales by Application (2023-2028) & (K Doses)
Table 77. Europe Rare Disease Drug Revenue by Application (2017-2022) & (US$ Million)
Table 78. Europe Rare Disease Drug Revenue by Application (2023-2028) & (US$ Million)
Table 79. Europe Rare Disease Drug Sales by Country (2017-2022) & (K Doses)
Table 80. Europe Rare Disease Drug Sales by Country (2023-2028) & (K Doses)
Table 81. Europe Rare Disease Drug Revenue by Country (2017-2022) & (US$ Million)
Table 82. Europe Rare Disease Drug Revenue by Country (2023-2028) & (US$ Million)
Table 83. Asia Pacific Rare Disease Drug Sales by Company (2017-2022) & (K Doses)
Table 84. Asia Pacific Rare Disease Drug Sales Market Share by Company (2017-2022)
Table 85. Asia Pacific Rare Disease Drug Revenue by Company (2017-2022) & (US$ Million)
Table 86. Asia Pacific Rare Disease Drug Revenue Market Share by Company (2017-2022)
Table 87. Asia Pacific Rare Disease Drug Sales by Type (2017-2022) & (K Doses)
Table 88. Asia Pacific Rare Disease Drug Sales by Type (2023-2028) & (K Doses)
Table 89. Asia Pacific Rare Disease Drug Revenue by Type (2017-2022) & (US$ Million)
Table 90. Asia Pacific Rare Disease Drug Revenue by Type (2023-2028) & (US$ Million)
Table 91. Asia Pacific Rare Disease Drug Sales by Application (2017-2022) & (K Doses)
Table 92. Asia Pacific Rare Disease Drug Sales by Application (2023-2028) & (K Doses)
Table 93. Asia Pacific Rare Disease Drug Revenue by Application (2017-2022) & (US$ Million)
Table 94. Asia Pacific Rare Disease Drug Revenue by Application (2023-2028) & (US$ Million)
Table 95. Asia Pacific Rare Disease Drug Sales by Region (2017-2022) & (K Doses)
Table 96. Asia Pacific Rare Disease Drug Sales by Region (2023-2028) & (K Doses)
Table 97. Asia Pacific Rare Disease Drug Revenue by Region (2017-2022) & (US$ Million)
Table 98. Asia Pacific Rare Disease Drug Revenue by Region (2023-2028) & (US$ Million)
Table 99. Latin America Rare Disease Drug Sales by Company (2017-2022) & (K Doses)
Table 100. Latin America Rare Disease Drug Sales Market Share by Company (2017-2022)
Table 101. Latin America Rare Disease Drug Revenue by Company (2017-2022) & (US$ Million)
Table 102. Latin America Rare Disease Drug Revenue Market Share by Company (2017-2022)
Table 103. Latin America Rare Disease Drug Sales by Type (2017-2022) & (K Doses)
Table 104. Latin America Rare Disease Drug Sales by Type (2023-2028) & (K Doses)
Table 105. Latin America Rare Disease Drug Revenue by Type (2017-2022) & (US$ Million)
Table 106. Latin America Rare Disease Drug Revenue by Type (2023-2028) & (US$ Million)
Table 107. Latin America Rare Disease Drug Sales by Application (2017-2022) & (K Doses)
Table 108. Latin America Rare Disease Drug Sales by Application (2023-2028) & (K Doses)
Table 109. Latin America Rare Disease Drug Revenue by Application (2017-2022) & (US$ Million)
Table 110. Latin America Rare Disease Drug Revenue by Application (2023-2028) & (US$ Million)
Table 111. Latin America Rare Disease Drug Sales by Country (2017-2022) & (K Doses)
Table 112. Latin America Rare Disease Drug Sales by Country (2023-2028) & (K Doses)
Table 113. Latin America Rare Disease Drug Revenue by Country (2017-2022) & (US$ Million)
Table 114. Latin America Rare Disease Drug Revenue by Country (2023-2028) & (US$ Million)
Table 115. Middle East and Africa Rare Disease Drug Sales by Company (2017-2022) & (K Doses)
Table 116. Middle East and Africa Rare Disease Drug Sales Market Share by Company (2017-2022)
Table 117. Middle East and Africa Rare Disease Drug Revenue by Company (2017-2022) & (US$ Million)
Table 118. Middle East and Africa Rare Disease Drug Revenue Market Share by Company (2017-2022)
Table 119. Middle East and Africa Rare Disease Drug Sales by Type (2017-2022) & (K Doses)
Table 120. Middle East and Africa Rare Disease Drug Sales by Type (2023-2028) & (K Doses)
Table 121. Middle East and Africa Rare Disease Drug Revenue by Type (2017-2022) & (US$ Million)
Table 122. Middle East and Africa Rare Disease Drug Revenue by Type (2023-2028) & (US$ Million)
Table 123. Middle East and Africa Rare Disease Drug Sales by Application (2017-2022) & (K Doses)
Table 124. Middle East and Africa Rare Disease Drug Sales by Application (2023-2028) & (K Doses)
Table 125. Middle East and Africa Rare Disease Drug Revenue by Application (2017-2022) & (US$ Million)
Table 126. Middle East and Africa Rare Disease Drug Revenue by Application (2023-2028) & (US$ Million)
Table 127. Middle East and Africa Rare Disease Drug Sales by Country (2017-2022) & (K Doses)
Table 128. Middle East and Africa Rare Disease Drug Sales by Country (2023-2028) & (K Doses)
Table 129. Middle East and Africa Rare Disease Drug Revenue by Country (2017-2022) & (US$ Million)
Table 130. Middle East and Africa Rare Disease Drug Revenue by Country (2023-2028) & (US$ Million)
Table 131. Novartis AG Corporation Information
Table 132. Novartis AG Description and Overview
Table 133. Novartis AG Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2017-2022)
Table 134. Novartis AG Rare Disease Drug Product and Services
Table 135. Novartis AG Rare Disease Drug SWOT Analysis
Table 136. Novartis AG Recent Developments
Table 137. Bristol-Myers Squibb Company Corporation Information
Table 138. Bristol-Myers Squibb Company Description and Overview
Table 139. Bristol-Myers Squibb Company Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2017-2022)
Table 140. Bristol-Myers Squibb Company Rare Disease Drug Product and Services
Table 141. Bristol-Myers Squibb Company Rare Disease Drug SWOT Analysis
Table 142. Bristol-Myers Squibb Company Recent Developments
Table 143. Celgene Corporation Corporation Information
Table 144. Celgene Corporation Description and Overview
Table 145. Celgene Corporation Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2017-2022)
Table 146. Celgene Corporation Rare Disease Drug Product and Services
Table 147. Celgene Corporation Rare Disease Drug SWOT Analysis
Table 148. Celgene Corporation Recent Developments
Table 149. F. Hoffmann-La Roche Ltd. Corporation Information
Table 150. F. Hoffmann-La Roche Ltd. Description and Overview
Table 151. F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2017-2022)
Table 152. F. Hoffmann-La Roche Ltd. Rare Disease Drug Product and Services
Table 153. F. Hoffmann-La Roche Ltd. Rare Disease Drug SWOT Analysis
Table 154. F. Hoffmann-La Roche Ltd. Recent Developments
Table 155. Pfizer, Inc. Corporation Information
Table 156. Pfizer, Inc. Description and Overview
Table 157. Pfizer, Inc. Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2017-2022)
Table 158. Pfizer, Inc. Rare Disease Drug Product and Services
Table 159. Pfizer, Inc. Rare Disease Drug SWOT Analysis
Table 160. Pfizer, Inc. Recent Developments
Table 161. Sanofi S.A. Corporation Information
Table 162. S